Bionano Genomics, INC 8-K filings

Bionano Genomics held its 2024 Annual Meeting of Stockholders, electing three Class III directors, approving executive compensation on an advisory basis, and ratifying its independent auditor.

Bionano Genomics has finalized a private placement of senior secured convertible debentures, raising $18 million to retire existing debt and improve its financial flexibility.

Bionano Genomics announced an 18% year-over-year revenue increase for Q1 2024, alongside strategic cost-saving initiatives and advancements in their optical genome mapping technology.

Bionano Genomics has announced a registered direct offering of common stock, pre-funded warrants, and warrants to purchase common stock.

Bionano Genomics has announced a $10 million registered direct offering priced at-the-market, involving the sale of common stock and warrants.

Bionano Genomics is implementing a corporate reorganization, including a significant workforce reduction, while reporting a 30% revenue increase for both Q4 and full-year 2023.

Bionano Genomics has amended its convertible debt financing agreement, reducing debt and increasing near-term liquidity.